Skip to main content

Riggs Rory B's Form 4 filing

Royalty Pharma plc (RPRX) · filed Dec 30, 2021

Accession no.
0001209191-21-071640
Filed
Dec 30, 2021
Trade date
Dec 28-29, 2021
Filing delay
2 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 9 non-derivative transactions. Open-market sales total $7.40M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Riggs Rory BCIK 0001016835Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Dec 28, 2021Class A Ordinary SharesJOtherAcquired+3,212–F2–625,610Direct
Dec 28, 2021Class A Ordinary SharesJOtherAcquired+42,138–F2–667,748Direct
Dec 28, 2021Class A Ordinary SharesJOtherDisposed−150,997–F4–349,552Indirect
Dec 28, 2021Class A Ordinary SharesJOtherDisposed−707,155–F5–1,142,415Indirect
Dec 28, 2021Class A Ordinary SharesJOtherDisposed−407,400–F6–708,245Indirect
Dec 28, 2021Class A Ordinary SharesSSaleDisposed−47,578$40.21F7−$1,913,111.38301,974Indirect
Dec 28, 2021Class A Ordinary SharesSSaleDisposed−26,677$40.21F7−$1,072,682.171,115,738Indirect
Dec 28, 2021Class A Ordinary SharesSSaleDisposed−35,193$40.21F8−$1,415,110.53673,052Indirect
Dec 29, 2021Class A Ordinary SharesSSaleDisposed−75,000$40.00F9−$3,000,000592,748Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

Pro rata distribution from a limited liability company of which the Reporting Person is a member.

Referenced by the price of 2 transactions in Table I.

F4

New Ventures Select distributed these shares to its members on a pro rata basis, for no consideration.

Referenced by the price of 1 transaction in Table I.

F5

New Ventures I LLC distributed these shares to its members on a pro rata basis, for no consideration.

Referenced by the price of 1 transaction in Table I.

F6

New Ventures III LLC distributed these shares to its members on a pro rata basis, for no consideration.

Referenced by the price of 1 transaction in Table I.

F7

The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.05 to $40.57 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 2 transactions in Table I.

F8

The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.02 to $40.57 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

F9

The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.85 to $40.29 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)